Support teaching, research, and patient care.
Molecular imaging in oncologyPeripheral Nerve ImagingCellular imaging of musculoskeletal inflammatory diseasesKinematic musculoskeletal imagingMagnetic resonance imaging of hepatic disorders
Combined F-18 NaF and F-18 FDG PET/CT for Evaluation of Malignancy Not Recruiting
Fluorine-18 Fluorodeoxyglucose (F-18 FDG) PET/CT is established as a powerful imaging tool for cancer detection and monitoring response to therapy. Sodium Fluorine-18 (F-18) was used in the 1970s for bone scanning and can be used as a skeletal tracer in current PET/CT scanners. The combined administration of F-18 and F-18 FDG in a single PET/CT scan for cancer detection was not attempted to date. We hope to learn what is the best approach for detection of cancer and thus to improve cancer treatment.
Stanford is currently not accepting patients for this trial. For more information, please contact Andrei Iagaru, 650-736-2859.
View full details
A Pilot Trial Using BR55 Ultrasound Contrast Agent in the Assessment of Prostate Cancer Not Recruiting
Pilot study to evaluate the ability of BR55 to identify prostate cancer lesions with Gleason Score ≥7 by ultrasound molecular imaging on the basis of a visual score in comparison with histopathology results
Stanford is currently not accepting patients for this trial. For more information, please contact Phuong Pham, 650-725-9810.
BR55 in Characterization of Ovarian Lesions Not Recruiting
This is an exploratory phase II, single center, open label, prospective study of BR55 CEUS for characterization of ovarian lesions in subjects with suspected ovarian cancer.
Stanford is currently not accepting patients for this trial. For more information, please contact Aya Kamaya, 650-723-8463.
